Novel treatment paradigm for elderly patients with multiple myeloma. by Palumbo, A & Magarotto, V.
  
Introduction 
 
Multiple myeloma (MM) is the second most 
common hematologic malignancy. It accounts 
for 1% of all cancers and 13% of hematologic 
neoplasms. The median age at diagnosis is 70 
years, with 37% of patients younger than 65 
years, 26% aged 65 to 74 years, and 37% older 
than 75 years [1 - 3]. 
 
The diagnosis of MM is based on the presence 
of at least 10% clonal bone marrow plasma 
cells and serum and/or urinary monoclonal pro-
tein [4, 5]. The disease is classified as sympto-
matic or asymptomatic. Symptomatic MM is 
characterized by evidence of end-organ damage 
caused by plasma cell proliferation, and it is 
defined by the presence of the CRAB features, 
namely hypercalcemia, renal failure, anaemia, 
and bone disease. Recognizing organ damage is 
essential in order to identify symptomatic MM 
[4, 5]. Treatment should be started immediately 
for patients with symptomatic disease; while 
asymptomatic MM only requires clinical obser-
vation, since early treatment has shown no 
benefit [6, 7]. Patients are stratified into three 
risk groups according to the International Stag-
ing System (ISS). Risk groups are based on se-
rum ß2-microglobulin and albumin levels at di-
agnosis [8]. High risk diseases and poor progno-
sis are defined with the presence of high levels 
of serum ß2-microglobulin (stage III). Cytoge-
netic abnormalities, detected by fluorescence in 
situ hybridization (FISH) are, in some cases, 
associated with worse outcome and a more ag-
gressive approach is required. The presence of 
deletion 17p13, translocation t(4;14)  t(14;16) 
or chromosome 1 abnormalities are  associated 
with poor prognosis (Figure 1) [9, 10]. 
 
Patient characteristics have a significant role in 
the treatment planning: patients younger than 
65 years, without severe comorbidities, who are 
able to undergo intensive treatment, are consid-
ered eligible for autologous stem cell transplan-
tation (ASCT). Patients older than 65 years or 
with serious comorbidities are usually not con-
sidered ASCT candidates and need a gentler 
approach. As the biological age may differ from 
the chronological age, it is necessary to con-
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sider comorbidities when determining eligibility 
of patients for ASCT [11]. 
 
For more than 40 years, melphalan-prednisone 
(MP) was considered the standard treatment in 
the transplant-ineligible setting. A meta-analysis 
of 27 randomized trials compared different che-
motherapy combinations with MP. Chemother-
apy induced higher responses (60.0% vs 53.2%, 
P<0.0001) but similar median OS (generally no 
more than 3 years), and MP was better toler-
ated [12].  
 
The introduction of novel agents, such as the 
immunomodulatory drugs (IMIDs) thalidomide 
and lenalidomide, and the first in-class protea-
some inhibitor bortezomib led to great advances 
in the treatment of this rare disease [13]. The 
major goal of treatment is to prolong both pro-
gression-free survival (PFS) and overall survival 
(OS). However, newer and more efficacious 
therapies enabled to achieve a complete re-
sponse (CR) in a larger proportion of patients. In 
the transplant setting, CR was found to be 
closely related to OS [14]. With the availability 
of novel agents, a greater number of elderly 
patients are now able to obtain a CR. A recent 
analysis on 1,175 elderly patients showed a 
significant association between the achieve-
ment of CR and long-term outcome, thus sup-
porting the use of novel agents to achieve maxi-
mal response also in patients over 75 years 
[15]. 
 
This paper will provide an update of MM treat-
ment in the elderly population, based on the 
results of the most recent trials and meta-
analyses.   
 
Thalidomide-based regimens 
 
The combination of thalidomide with high dose 
dexamethasone (TD) showed higher efficacy 
compared to the old standard MP, but toxicity 
and treatment discontinuation were higher with 
dexamethasone. The rate of non-disease-
related mortality in the TD group was twice as 
high as in the MP group, and infections were the 
Figure 1. Patient risk-stratification and prognosis 
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Table 1. Management of adverse events in multiple myeloma patients treated with novel agents 
Toxicity 
Novel agent 
suspected to cause 
the event 
How to manage the event Dose-adjustment recommended 
Neutropenia Lenalidomide, Bortezomib  
G-CSF until neutrophil recovery in case of uncomplicated grade 4 AE or grade 
2-3 AEs complicated by fever or infection. 25% to 50% drug reduction 
Thrombocytopenia Bortezomib, Lenalidomide  Platelet transfusion in case of occurrence of grade 4 AE. 25% to 50% drug reduction 
Anaemia Bortezomib, Lenalidomide  Erythropoietin or darbepoietin if hemoglobin level is ≤ 10 g/dL. 25% to 50% drug reduction 
Infection All  
Trimetoprin-cotrimoxazole for Pneumocystis carinii prophylaxis during high-
dose dexamethasone. Acyclovir or valacyclovir for HVZ prophylaxis during 
bortezomib-containing therapy. 
25% to 50% drug reduction 
Neurotoxicity Bortezomib, Thalidomide  
Neurological assessment before and during treatment. Prompt dose reduction 
is recommended 
Bortezomib: 25%-50% reduction for grade  1 with pain or grade 2 
peripheral neuropathy; dose interruption until peripheral 
neuropathy resolves to grade 1 or better with restart at 50% 
dose reduction for grade 2 with pain or grade 3 peripheral 
neuropathy; treatment discontinuation for grade 4 peripheral 
neuropathy. Thalidomide: 50% reduction for grade 2 neuropathy; 
discontinuation for grade 3; resume Thalidomide at a decreased 
dose if neuropathy improves to grade 1. 
Skin toxicity Thalidomide, Lenalidomide  Steroids and antihistamines. 
Interruption in case of grade 3-4 AE. 
50% reduction in case of grade 2 AE. 
Gastrointestinal toxicity All  Appropriate diet, laxatives, physical exercise, hydration, antidiarrheics. Interruption in case of grade 3-4 AEs 50% reduction in case of grade 2 AEs. 
Thrombosis Thalidomide, Lenalidomide  
Aspirin 100-325 mg if no or one individual/myeloma thrombotic risk factor is 
present. LMWH or full dose warfarin if there are two or more 
individual/myeloma risk factors and in all patients with thalidomide-related 
risk factors. 
Drug temporary interruption and full anticoagulation, then 
resume treatment 
Renal toxicity Lenalidomide Correct precipitant factors (dehydration, hypercalcemia, hyperuricemia, urinary infections, and concomitant use of nephrotoxic drugs). 
Reduce dose according to creatinine clearance: 
If 30-60 mL/min: 10 mg/day; 
If < 30 mL/min without dialysis needing: 15 mg every other day; 
If < 30 mL/min with dialysis required: 5 mg/day after dialysis on 
dialysis day. 
Bone pain None 
Start with simple non-opioid analgesics. If no improvement is detected 
continue with weak opioid analgesics. In case of no relief, use synthetic 
opioids or strong (natural) opioids. Local radiotherapy is also an effective 
strategy. 
----- 
Bone disease None 
Vetebropalsty (percutaneous injection of polymethacrylate or equivalent 
material into the vertebral body). Use of balloon kyphoplasty enhances 
vertebral height. Long-term bisphosphonates may prevent bone disease.  
Further strategies are intravenous pamidronate, intravenous zoledronic acid 
as well as oral clodronate. 
----- 
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main cause. This was even more evident in pa-
tients older than 72 years with poor perform-
ance status [16]. Prompt and appropriate man-
agement of the main adverse events (Table 1), 
the choice of different steroids (eg. prednisone 
vs dexamethasone) and treatment schedules 
tailored on patients characteristics (Table 2) 
may be crucial for the success of the treatment 
itself, enabling patients to stay on treatment 
longer and to benefit more from it. 
 
The combination of melphalan-prednisone-
thalidomide (MPT) was compared to MP in six 
randomized phase 3 studies [17-22]. The two 
Intergroupe Francophone du Myelome (IFM) 
studies showed that both PFS and OS were 
higher in the MPT arm [17, 18]. The Italian trial 
observed a PFS advantage that did not translate 
into a survival advantage for patients treated 
with thalidomide [22]. The Dutch/Belgian study 
detected differences in PFS/OS and event free 
survival (EFS) between the two treatment arms 
[21]. The Nordic trial did not find significant dif-
ference in terms of PFS and OS,  although re-
sponse were significantly better during the first 
year of treatment with MPT [20]. 
 
Finally, the Turkish trial detected considerably 
higher responses in MPT patients, as well as an 
initial not significant survival advantage in the 
MPT arm during the first six months of treat-
ment [19]. In all these studies, grade 3–4 neu-
tropenia was the main adverse event associ-
ated with MPT (16-48%), mostly related to mel-
phalan. Peripheral neuropathy (6-23%) and ve-
nous thromboembolism (3-12%) were the main 
adverse events associated with thalidomide. 
Concomitant anti-thrombotic prophylaxis with 
aspirin, warfarin, or low molecular weight hepa-
rin is suggested [23].  
 
Data from the MPT trials mentioned above were 
pooled together in a meta-analysis of 1,685 
patients [24]. Median survival was 32.7 months 
with MP vs 39.3 months with MPT. This differ-
ence was more pronounced at 3 and 4 years, 
with early deaths in the MPT arm during the first 
year of therapy. This may suggest a lack of ad-
vantage of MPT over MP during the first year of 
therapy. Two-years PFS was 28.4% in MP and 
42.5% in MPT. Responses were higher in the 
MPT arm, in particular very good partial re-
sponse (VGPR) which was 9% with MP vs 25% 
with MPT. In this meta-analysis, correlation be-
tween OS/PFS and risk factors such as ISS, 
Durie/Salmon stages, performance status (WHO
-PS), haemoglobin and/or creatinine values and 
others were difficult to demonstrate, because of 
the heterogeneity of patient baseline character-
istics in each study. In particular, the meta-
analysis failed to demonstrate that patients with 
poor performance status or with renal failure 
Table 2. Recommended dose reductions according to age 
Drug 65-75 years > 75 years Further reduction 
Dexamethasone 40 mg/d d 1,8,15,22 every 4 wks 
20 mg/d 
d 1,8,15,22 every 4 wks 
10 mg/d 
d 1,8,15,22 every 4 wks 
Melphalan 0.25 mg/kg or 9 mg/m
2 
d 1-4 every 4-6 wks 
0.18 mg/kg or 7.5 mg/m2 
d 1-4 every 4-6 wks 
0.13 mg/kg or 5 mg/m2 
d 1-4 every 4-6 wks 
Thalidomide 100 mg/d 50 mg/d 50 mg qod 
Lenalidomide (plus 
dexamethasone) 
25 mg/d 
d 1-21 every 4 wks 
15 mg/d 
d 1-21 every 4 wks 
10 mg/d 
d 1-21 every 4 wks 
Lenalidomide (plus 
melphalan-prednisone) 
10 mg/d 
d 1-21 every 4 wks 
5 mg/d 
d 1-21 every 4 wks 
5 mg qod 
d 1-21 every 4 wks 
Bortezomib 1.3 mg/m
2 twice weekly 
d 1,4,8,11 every 3 wks 
1.3 mg/m2 once weekly 
d 1,8,15,22 every 5 wks 
1.0 mg/m2 once weekly 
d 1,8,15,22 every 5 wks 
Prednisone 60 mg/m2 d 1-4 30 mg/m2 d 1-4 15 mg/m
2 d 1-4 
  
Cyclophosphamide 100 mg/d d1-21 every 4 wks 
50 mg/d 
d 1-21 every 4 wks 
50 mg qod 
d 1-21 every 4 wks 
d, day; wk, week; qod, every other day 
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should not be treated with MPT. The sample 
size of patients with WHO-PS >2 or with high 
creatinine level was limited to draw definitive 
conclusions. Despite the limits of this meta-
analysis, such as the heterogeneity of patient 
characteristics and the different treatment 
schedules, MPT improved OS and PFS in previ-
ously untreated MM patients, extending the 
median OS time by 20%. No advantage with 
MPT was found in patients with poor PS or renal 
impairment. 
    
Based on these results, MPT is now considered 
a standard of care for elderly patients with MM. 
 
Morgan et al. compared MP with a new thalido-
mide-based regimen, substituting melphalan 
with cyclophosphamide and prednisone with 
dexamethasone (CTD) in newly diagnosed eld-
erly MM patients [25]. The overall response rate 
(ORR) was significantly higher in CTD than in MP 
group (63.8% vs 32.6% respectively, 
P<0.0001). After a median follow-up of 44 
months, no difference in terms of PFS (median 
12.4 months in the MP group vs 13 months in 
the CTD group) and OS (median 30.6 months 
with MP vs 33.2 months with CTD) was evi-
denced. Of note, patients with a good cytoge-
netic profile at FISH benefited from CTD and 
had improved OS, especially after the first 18 
months of treatment. OS benefit was observed 
in all patients who reached CR, independently 
from the treatment received. 
 
The most frequent (≥ 10%) adverse events oc-
curred in the CTD arm were constipation (41%), 
infection (32%), sensory neuropathy (24%), and 
deep vein thrombosis (DVT) (16%), Thrombopro-
phylaxis was not mandatory initially. It was then 
introduced for patients in the CTD group, and 
thromboembolic events decreased dramatically. 
Considering the results achieved,  CTD is a valid 
alternative for selected elderly newly diagnosed 
MM patients, with more benefits in those with 
good genetic profile. Prompt reduction of drug 
doses in case of adverse events is suggested to 
enable patients to stay on treatment for a 
longer time and benefit from it. 
 
Based on the studies described above, the as-
sociation of thalidomide with steroids and alky-
lant agents is a good option for elderly MM pa-
tients. In particular MPT has been approved by 
the European agency for drug administration 
(EMA) as therapy for new diagnosed MM not 
eligible to ASCT and is now considered the new 
standard of care in this setting.  
 
Lenalidomide-based regimens 
 
Recently, a phase 3 trial compared lenalido-
mide plus high-dose dexamethasone (RD) vs 
lenalidomide plus low-dose dexamethasone 
(Rd), in both young and elderly patients with 
new diagnosed MM (Table 3) [26]. Toxicity rates 
were significantly higher with RD, in particular 
DVT or pulmonary embolism (PE) (26% vs 12%), 
and infections (16% vs 9%). Considering its 
good toxicity profile, almost all recent trials are 
adopting the reduced-dose of dexamethasone 
(namely 40 mg once weekly or equivalent) and 
the use of high-dose dexamethasone is no 
longer recommended in newly diagnosed MM, 
especially in elderly patients. High dose dexa-
methasone is indicated in particular settings, 
when hypercalcemia, spinal cord compression, 
renal failure and pain occur at diagnosis. 
 
The addition of lenalidomide to standard MP 
(MPR) led to impressive results [27]. A phase 1-
2 dose-escalating open-label study evaluated 
the role of MPR in 50 new diagnosed MM pa-
tients, not eligible for ASCT. Treatment con-
sisted of nine 28-day cycles of MPR combina-
tion, followed by maintenance therapy with le-
nalidomide alone. Aspirin was given as thrombo-
prophylaxis. 
 
The maximum tolerated dose (MTD) was de-
fined as 0.18 mg/kg melphalan and 10 mg/day 
lenalidomide. With these doses, 81% of patients 
achieved at least a partial response (PR), 47.6% 
achieved a VGPR and 23.8% achieved a CR. In 
all patients, 1-year EFS was 92% and OS was 
100%. At the MTD, grade 3 adverse events in-
cluded neutropenia (38.1%), thrombocytopenia 
(14.2%), febrile neutropenia (9.5%), vasculitis 
(9.5%) and thromboembolism (4.8%). Grade 4 
adverse events were neutropenia (14.2%) and 
thrombocytopenia (9.5%). At the maximum tol-
erated dose, grade 3-4 adverse events were 
primarily hematologic, while non-hematologic 
adverse events were less than 10%, especially 
DVT, thanks to the use of aspirin. Peripheral 
neuropathy was never observed. A phase 3 
study is comparing MPR vs MPR followed by 
lenalidomide maintenance (MPR-R) vs MP is 
underway [28]. Preliminary data showed that 
MPR-R reduced the risk of disease progression 
by 58% compared with MP. A landmark analysis 
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Table 3. Novel-agent containing induction regimens for elderly patients with multiple myeloma 
 Combination No. of 
patients 
Schedule ≥ PR  CR  PFS/EFS/TTP OS Reference 
T
h
a
l
i
d
o
m
i
d
e
-
b
a
s
e
d
 
TD 145 
T: 200 mg/day 
D: 40 mg, days 1-4 and 15-18 on even 
cycles and days 1-4 on odd cycles, 
during a 28-day cycle 
68% 2% 41% at 16 mo 61% at 41 mo [18]  
MPT 125 
M: 0.25 mg/kg day1–4 
P: 2 mg/kg day 1–4 
T: 400 mg/day 
for twelve 6-week cycles 
76% 13% 50% at 28 mo 50% at 52 mo [17]  
MPT 113 
M: 0.25 mg/kg day 1–4 
P: 2 mg/kg day 1–4 
T: 100 mg/day 
for twelve 6-week cycles 
62% 7% 50% at 24 mo 50% at 44 mo [18]  
MPT 60 
M: 9 mg/m2 days 1–4 
P: 60 mg/m2 days 1–4 
T: 100 mg/day for 8 
6-week cycles, followed by 
T: 100 mg/day until relapse 
58% 9% 50% at 21 mo* 50% at 26 mo [19] 
MPT 182 
M: 0.25mg/kg days 1-4 
P: 100mg/day days 1-4 
For 6-week cycles until plateau 
T: 400mg/day until plateau, reduced to 200mg/day until 
progression 
57% 13% 50% at 15 mo 50% at 29 mo [20]  
MPT 165 
M: 0.25 mg/kg 
P: 1 mg/kg days 1–5 
T: 200 mg/day for 8 
4-week cycles, followed by 
T: 50 mg/day until relapse 
66% 23%# 67% at 24 mo 29% at 24 mo [21]  
MPT 167 
M: 4mg/m2 days 1-7 
P: 40mg/m2 days 1-7 for six 4-week cycles 
T: 100mg/day until relapse 
76% 15% 50% at 22 mo 50% at 45 mo [22]  
CTD 426 
C: 500 mg/week 
T: 50 mg for 4 weeks and increased every 4 weeks in 50 mg to a 
maximum of 200 mg/day 
D: 20 mg/day days 1-4 and 15-18 of each 28-cycle 
64% 13% 50% at 13 mo 50% at 33 mo [25]  
L
e
n
a
l
i
d
o
m
i
d
e
-
b
a
s
e
d
 
RD§ 223 
R: 25 mg/day on day 1-21 
D: 40 mg on day 1-4, 9-12, and 17-20 of a 28-day cycle 81% 17% 
63% at 24 
mo 75% at 24 mo [26]  
Rd§ 222 
R: 25 mg/day on day 1-21 
d: 40 mg on days 1, 8, 15 and 22 of a 28-day cycle 70% 14% 65% at 24 mo 87% at 24 mo [26]  
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MPR 54 
M: 0.18-0.25 mg/kg days 1–4 
P: 2 mg/kg days 1–4 
R: 5-10 mg days 1–21  
for nine 4-week cycles 
81% 24% 92% at 12 mo 
100% at 12 
mo [27]  
MPR-R 152 
M: 0.18 mg/kg days 1–4 
P: 2 mg/kg days 1–4 
R:10 mg days 1–21  
for nine 4-week cycles 
 
Maintenance 
R: 10 mg/day until relapse 
77% 16% 50% at 31 mo 92% at 12 mo [28]  
CRD 53 
C: 300 mg/m2 days 1,8,15 
R: 25 mg/day days 1-21 
D: 40 mg days 1,8,15,22 (weekly continuously) 
79% 2% 50% at 28 mo 87% at 24 mo [29]  
B
o
r
t
e
z
o
m
i
b
-
b
a
s
e
d
 
VMP 344 
M: 9 mg/m2 days 1–4 
P: 60 mg/m2 days 1–4 
V: 1.3 mg/m2 days 
1,4,8,11,22,25,29,32 for  
first four 6-week cycles; days 1,8,15, 22 for subsequent 
five 6-week cycles 
71% 30% 50% at 22 mo 41% at 36 mo 
[31, 32]  
 
VMP 257 
M: 9 mg/m2 day 1–4 
P: 60 mg/m2 day 1–4 
V: 1.3 mg/m2 day 1, 8, 15, 22 
81% 24% 41% at 36 mo 87% at 36 mo [35]  
VMP 130 
M: 9 mg/m2 day 1–4 
P: 60 mg/m2 day 1–4 
V: 1.3 mg/m2 twice weekly 
(day 1,4,8,11,22,25,29, and 32) 
for one 6-week cycle, followed by 
once weekly (day 1, 8, 15, and 22) 
for five 5-week cycles 
 
Maintenance: 
V:1.3 mg/m2 twice weekly on 
days 1, 4, 8, 11, every 3 months 
T: 50 mg/day 
                Or 
V: 1.3 mg/m2 twice weekly 
on days 1, 4, 8, 11, every 3 months 
P: 50 mg every other day 
89% 20% 50% at 34 mo 74% at 36 mo [34]  
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VTP 130 
T: 100 mg/day 
P: 60 mg/m2 day 1–4 
V: 1.3 mg/m2 twice weekly 
(day 1, 4, 8, 11, 22, 25, 29 and 32) 
for one 6-week cycle, followed by 
once weekly (day 1, 8, 15 and 22) 
for five 5-week cycles 
 
Maintenance: 
V:1.3 mg/m2 twice weekly on 
days 1, 4, 8, 11, every 3 months 
T: 50 mg/day 
                Or 
V: 1.3 mg/m2 twice weekly 
on days 1, 4, 8, 11, every 3 months 
P: 50 mg every other day 
81% 28% 50% at 25 mo 65% at 36 mo [34]  
VMPT-VT 254 
M: 9 mg/m2 day 1–4 
P: 60 mg/m2 day 1–4 
V: 1.3 mg/m2 day 1, 8, 15, 22 
T: 50 mg day 1–42 for nine 
5-week cycles 
 
Maintenance 
V: 1.3 mg/m2 every 15 days 
T: 50 mg/day 
89% 38% 56% at 36 mo 89% at 36 mo [35]  
PR, partial response; CR, complete response; PFS, progression-free survival; EFS, event-free survival; TTP, time to progression; OS, overall survival; TD, thalidomide-
dexamethasone; MPT, melphalan-prednisone-thalidomide; CTD: cyclophosphamide-thalidomide-dexamethasone; RD: lenalidomide plus high dose dexamethasone; Rd: 
lenalidomide plus low dose dexamethasone; MPR, melphalan-prednisone-lenalidomide; CRD: cyclophosphamide-lenalidomide-dexamethasone; MPR-R: MPR followed by 
lenalidomide maintenance; VMP, bortezomib-melphalan-prednisone; VTP, bortezomib-thalidomide-prednisone;; VMPT-VT, bortezomib-melphalan-prednisone-thalidomide 
followed by bortezomib-thalidomide maintenance; NA, not available; mo, months. 
 
§ The study included both young and elderly patients  
* Disease-free survival 
# CR plus VGPR  
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proved the benefit of maintenance with le-
nalidomide: the risk of progression in the MPR-R 
arm was reduced by 69% compared to MPR. 
Grade 3–4 hematologic toxicities were more 
common with MPR-R than with MP (neutropenia 
71% vs 30%, thrombocytopenia 38% vs 14%). 
Lenalidomide maintenance was well tolerated, 
and few serious adverse events were reported. 
It is worth mentioning that antithrombotic pro-
phylaxis is highly recommended in patients re-
ceiving lenalidomide or thalidomide as induc-
tion therapies [23]. Based on these studies, 
MPR combination should be considered another 
valid alternative option for newly diagnosed MM 
elderly patients. 
 
The use of another alkylant agent, like cyclo-
phosphamide, in combination with lenalidomide 
and dexamethasone (CRD) led to promising 
results [29]. In a phase 2 trial, 53 patients pre-
viously untreated received at least 4 cycles of 
CRD combination. Both patients eligible and 
those not eligible for ASCT were included. The 
median age of patients was 64 years (range 37-
82 years). Forty-seven patients received at least 
4 cycles of CRD therapy. At least PR was de-
tected in 79% of patients, including  at least 
VGPR rate of 30%. The most common grade 3-4 
hematologic toxicity was neutropenia, that could 
be managed by reducing cyclophosphamide 
dose. Fatigue was the more frequent non-
hematologic toxicity. The incidence of DVT was 
about 15%, and thromboprophylaxis was not 
mandatory, but suggested only in high-risk pa-
tients. After a median follow-up of 37 months, 
the median OS for the entire group of patients 
was not reached, with an estimated OS rate of 
87% at 2 years. The 2-year PFS was 57% for the 
entire group.  
 
In high-risk patients, according to mSMART cri-
teria, the ORR was 93% (79% in those with stan-
dard risk) and the 2-yars PFS was 57% (61% in 
those with standard risk). OS was similar in the 
two group. A longer follow-up is needed to draw 
definitive conclusions. 
 
A multicentre phase 3 trial comparing Rd vs 
MPR vs CRD in elderly MM patients is ongoing. 
One of the objectives of the study is to establish 
if the addition of an alkylant to Rd combination 
improves response/outcome and which alkylat-
ing agent is more effective in combination with 
Rd. The results so far obtained support the use 
of MPR as a valid option for MM elderly pa-
tients.   
Bortezomib-based regimens 
 
The association of bortezomib and dexa-
methasone (VD) showed to be an effective and 
safe frontline approach both in patients eligible 
and ineligible for ASCT [30]. 
 
Forty-nine patients have been enrolled and re-
ceived bortezomib 1.3 mg/m2 on days 1, 4, 8, 
11 for a maximum of six 3-week cycles. Patients 
who did not reach PR after 2 cycles or CR after 
4 cycles received 40 mg of oral dexamethasone 
the day of and the day after bortezomib admini-
stration. Transplantation was not protocol-
specified. 
 
At least PR rate was 90%, with at least VGPR 
rate of 42%, and 19% patients in CR/ near CR.  
 
After a median follow-up of 49 months, in pa-
tients who did not receive ASCT, median PFS 
was 21 months and the median OS was not 
reached. Toxicity was moderate with few cases 
of grade 3-4 of neutropenia and peripheral neu-
ropathy. This trial confirmed the efficacy of VD 
combination also in patients who did not re-
ceived high dose therapy. Few adverse events 
were detected and no DVT cases were seen, 
although patients did not receive any thrombo-
prophylaxis.  
 
The combination bortezomib-melphalan-
prednisone (VMP) proved to be a valid alterna-
tive option for elderly patients. The phase 3 Vel-
cade as Initial Standard Therapy (VISTA) study 
compared standard MP to VMP and found that 
responses, particularly CR, time to progression 
(TTP) and survival were significantly higher with 
VMP compared to MP [31, 32]. Hematologic 
toxicities were similar in the two groups. Grade 
3–4 peripheral sensory neuropathy and neural-
gia were more frequent with VMP, so were 
grade 3–4 gastrointestinal events (19% vs 5%). 
Of note, a sub-group analysis of the VISTA trial, 
showed the importance to achieve CR, also in 
the elderly population [33] Patients who 
reached CR, independently from the arm of ran-
domization (MP or VMP), had a longer TTP, time 
to next therapy (TNT), and treatment free inter-
val (TFI) compared with those who reached 
VGPR or PR. However, this analysis failed to 
show an OS advantage for CR. A possible expla-
nation is the use of novel agent-containing com-
binations at relapse, that prolonged survival in 
patients who reached CR, VGPR or PR at the 
diagnosis. In the light of the impressive results 
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achieved, VMP has become a valid alternative 
for newly diagnosed elderly patients. 
 
Two phase 3 trials evaluated alternative combi-
nations. The Spanish Myeloma Group 
(PETHEMA/GEM) compared VMP regimen to the 
combinat ion  bor tezomib- thal idomide-
prednisone (VTP) as induction therapy, and 
weekly bortezomib was used for both arms [34]. 
Patients were then randomized to receive main-
tenance therapy with bortezomib-thalidomide 
(VT) or bortezomib-prednisone (VP) for 3 years. 
A major goal was to evaluate which one be-
tween thalidomide or prednisone was the best 
drug to use in combination with bortezomib. 
Another important objective was to optimize 
treatment by reducing toxicity (eg. by using the 
weekly infusion of bortezomib). Response rates 
were similar in the two arms, so were also the 2-
year TTP and OS. Nevertheless, VMP was better 
tolerated than VTP. Grade 3-4 cardiac toxicity 
was 8.5% vs 0 (P=0.001), thromboembolic 
events were 2% vs 1% (P=0.5) and peripheral 
neuropathy was 9% vs 5% (P=0.6) with VTP and 
VMP, respectively. Patients in the VMP arm had 
a higher rate of neutropenia (39% vs 22%, 
P=0.008), thrombocytopenia (27% vs 12%, 
P=0.0001) and infections (7% vs 1%, P=0.01). 
Discontinuation rate (17% vs 12%, P=0.03) and 
serious adverse events (31% vs 15%, P=0.01) 
were higher in the VTP arm. Maintenance ther-
apy led to a substantial increase in CR rate, with 
no considerable difference between VT or VP. 
This approach led to a longer TTP compared to 
the VISTA trial (35 moths vs 24 months, respec-
tively). No grade 3-4 hematologic toxicities were 
recorded during maintenance and less than 
10% of grade 3 peripheral neuropathy (more 
frequent in the VT arm) were reported. These 
data confirm the role of VMP and suggest that, 
considering its toxicity profile, VMP should be 
preferred to VTP. The weekly-schedule of borte-
zomib reduced peripheral neuropathy and gas-
trointestinal toxicity without affecting efficacy. 
 
A more complex approach including both tha-
lidomide and bortezomib in combination with 
MP followed by maintenance with bortezomib-
thalidomide (VMPT-VT) has been compared to 
the standard VMP. VMPT-VT led to higher re-
sponse rates and better PFS. No difference in 
OS was detected between the two arms, but 
follow-up is still short to draw definitive conclu-
sion. Grade 3–4 neutropenia (38% vs 28%, 
P=0.02), cardiac complications (10% vs 5%, 
P=0.04) and thromboembolic events (5% vs 2%, 
P=0.08) were more frequent with VMPT-VT [35, 
36]. The change of bortezomib schedule, from 
twice-weekly to once-weekly infusion in both 
arms,  improved tolerability of the regimens, 
reducing peripheral neuropathy incidence to 
less than 10% and prolonging the time of treat-
ment [37]. A subgroup analysis showed that in 
patients older than 75 years and in those with 
high risk disease (according to cytogenetic ab-
normalities and ISS) a more intensive regimen 
with VT maintenance does not add any signifi-
cant advantage (P=0.5). The 1-year landmark 
analysis of PFS demonstrated that VT reduced 
the risk of disease progression of 52% 
(P<0.0001) but this advantage was less evident 
in patients ≥75 years (P=0.87). A longer follow-
up is needed, particularly to assess OS. How-
ever, VMP-VT proved to be a valid options, espe-
cially for patients aged 65-75 years. 
 
Transplantation with reduced-dose melphalan 
 
Patients older than 65 years, as well as those 
with significant comorbidities, are generally not 
considered candidates for standard melphalan 
200mg/m2 followed by ASCT. A randomized trial 
exploring the efficacy of high-dose chemother-
apy and transplantation in patients with newly 
diagnosed MM found a considerably higher 5-
year OS in patients younger than 65 years un-
dergoing ASCT compared to elderly patients 
(68% vs 50%, P=0.008) [38]. Intermediate-dose 
regimens were proposed to adapt ASCT to older 
patients, by reducing potentially lethal side ef-
fects. Two randomized studies compared re-
duced-dose melphalan (Melphalan 100mg/m2 
— Mel100) followed by ASCT vs MP. The first 
study included patients between 65 and 70 
years, and showed that reduced-intensity ASCT 
(Mel100) leads to better EFS and OS as com-
pared to MP [39]. The second study included 
patients aged 65 to 75 years, and compared 
reduced-intensity ASCT vs MP vs MPT: in this 
trial, PFS and OS were longer in patients treated 
with MPT compared with MP or Mel100, and no 
differences between MP and reduced-intensity 
ASCT were observed [17]. A phase 2 trial evalu-
ated the safety and efficacy of bortezomib and 
lenalidomide incorporated in pre-transplant in-
duction and post-transplant consolidation/
maintenance, in patients aged 65–75 years, 
who received reduced-intensity ASCT (Mel100) 
[40]. The CR rate was 13% after induction with 
bortezomib, 43% after Mel100, and 73% during 
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consolidation/maintenance with lenalidomide. 
During induction therapy, grade 3–4 toxicities 
were thrombocytopenia (17%), neutropenia 
(10%), peripheral neuropathy (16%) and pneu-
monia (10%). Lenalidomide consolidation/
maintenance was well tolerated, with no cumu-
lative or persistent grade 3–4 neutropenia 
(16%) and/or thrombocytopenia (6%), pneumo-
nia (5%) and skin rash (4%) were the more fre-
quent extra-hematologic toxicities [33]. Data 
from these studies suggest that the reduced-
intensity ASCT is a valuable strategy for elderly 
patients, for whom full-dose chemotherapy and 
ASCT may be too toxic. A sequential approach, 
starting with bortezomib as induction, followed 
by reduced-intensity ASCT and then lenalido-
mide consolidation/maintenance, improves 
response quality and rate. Patients younger 
than 70 years showed a slightly better outcome 
compared with patients over 70 years. The inci-
dences of adverse events, early mortality and 
drop-outs suggest that Mel100 is more toxic for 
patients aged 71-75 years and should be con-
sidered for patients under 70 years of age.   
 
Therapy for very elderly patients  
 
So far, no precise guidelines are available to 
strictly define an age cut-off for the choice of 
treatment. The efficacy of a regimen should 
always be balanced against its toxicity, and age-
adjusted dose modifications are strongly sug-
gested to improve tolerability and treatment 
outcome (Table 2). Different studies tested the 
role of reduced-dose regimens in patients over 
75 years. The French MPT study investigated 
reduced-dose of melphalan (0.2 mg/kg) and 
thalidomide (100 mg/day) in patients older than 
75 years [18]. Median PFS was 24.1 months 
with MPT and OS was 44.0 months. Treatment-
related adverse events were acceptable, with a 
median thalidomide treatment duration over 1 
year. No increase in thrombosis was detected, 
probably thanks to the use of antithrombotic 
treatments.  
 
Similarly, both the Spanish and the Italian 
groups showed that, in elderly MM patients, the 
once-weekly schedule of bortezomib administra-
tion reduced toxicity, without negatively impact-
ing on efficacy [34, 37]. This approach led to a 
significant reduction in non-hematologic grade 3
-4 adverse events, particularly peripheral neu-
ropathy and, consequently, treatment discon-
tinuation rate [37]. On the other hand, the Ital-
ian trial showed that the intensive approach 
with VMP followed by VT maintenance seems 
not to add any significant advantage in terms of  
PFS in very elderly patients, over 75 years of 
age.  
 
Role of maintenance therapy  
 
There are only few studies on the role of mainte-
nance therapy in elderly patients. The Italian 
group assessed the role of maintenance with VT 
after VMPT induction. An exploratory analysis 
performed on the 82 VMPT-VT patients who 
received at least 6 months of VT maintenance 
showed an improvement in CR rate from 58% 
after 9 cycles of VMPT to 62% after 6 months of 
VT maintenance [35]. The 1-year landmark 
analysis of PFS demonstrated that VT reduced 
the risk of disease progression of 52% 
(P<0.0001) but this advantage was less evident 
in patients older than 75 years and in those 
with high risk disease (ISS stage III and adverse 
genetic profile). A longer follow-up is needed to 
draw definitive conclusions, especially in terms 
of OS. The Spanish group investigated the role 
of maintenance therapy with VP vs VT in elderly 
patients who had received VMP or VTP as induc-
tion. Overall, maintenance treatment improved 
CR rate (from 25% up to 42%), and no signifi-
cant differences in response rates between the 
two maintenance strategies were seen (38% 
and 46%, respectively with VP and VT). After a 
median duration of maintenance of 13 months, 
there was a trend towards a lower TTP with VP 
compared with VT (1-year TTP: 71% vs 84%; 
P=0.05), but no significant OS difference was 
detected (89% with VP vs 92% with VT) [34]. 
 
In the European Myeloma Network phase 3 
study, after induction with MPR, patients were 
randomized to receive lenalidomide or placebo 
maintenance until progression: a landmark 
analysis showed that lenalidomide maintenance 
after MPR induction decreased the risk of pro-
gression by 69%. The survival advantage was 
also confirmed in patients older than 75 years 
[28]. This impressive result lends support to the 
use of lenalidomide as maintenance therapy.  
 
Longer follow-up is needed to establish the ad-
vantage derived from bortezomib and lenalido-
mide as maintenance therapy in the elderly 
population. 
 
Conclusion 
 
Today, a wider variety of treatment options are 
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available for both young and elderly patients 
with MM. In elderly patients, randomized phase 
3 studies have shown that MPT and MPV are 
more effective than the traditional MP and thus 
they are considered the new standards of care 
in this setting. The combination MPR followed 
by lenalidomide maintenance showed to be a 
valid alternative. Considering the positive pre-
liminary results achieved, MPR followed by le-
nalidomide maintenance is likely to become an 
additional standard therapy for elderly MM pa-
tients soon. Impressive results were achieved 
with the more intensive treatment VMPT fol-
lowed by VT maintenance. Reducing bortezomib
-schedule from twice- to once-weekly admini-
stration is an appropriate and effective strategy 
to further improve outcome without negatively 
affecting efficacy. Recently, reduced-dose dexa-
methasone proved to be well tolerated in this 
population, and Rd may be a valid option for 
elderly MM patients. ASCT with a reduced mel-
phalan conditioning dose should be considered 
in selected elderly patients, not older than 70 
years. The choice among these regimens should 
be based on patient characteristics. Patients 
with renal impairment are eligible for borte-
zomib or thalidomide-containing regimens, 
since lenalidomide is excreted by kidneys and, 
in case of renal impairment, lenalidomide dose 
must be reduced according to creatinine clear-
ance. If patients suffer from peripheral neuropa-
thy, either myeloma related or not, bortezomib 
and thalidomide are not the best choice. On the 
contrary, lenalidomide-containing regimens 
should be considered for these patients be-
cause of the reduced neurologic toxicity associ-
ated with lenalidomide. 
 
A particular attention should be paid to alkylat-
ing agents and steroids schedule, especially in 
the very elderly population. In case of treatment
-related toxicity, a prompt suspension and sub-
sequent reduction of the drug can limit toxici-
ties. 
 
Thanks to the availability of novel agents, many 
steps forward have been made in the treatment 
of elderly MM patients. Phase 2-3 trials includ-
ing the new generation of IMIDs (Pomalidomide) 
and proteasome inhibitors (Carfilzomib) are cur-
rently ongoing in the elderly population, and 
their role in this setting may be validated in the 
near future.  
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